Features | Partner Sites | Information | LinkXpress
Sign In
PZ HTL SA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

Acquisition Should Increase Routine Flow Cytometry Diagnostic Use in Research and Clinical Practice

By BiotechDaily International staff writers
Posted on 13 Aug 2013
Image: The MoFlo XDP flow cytometer has set the standard for cell sorting with functionality, speed, and improved sensitivity (Photo courtesy of Beckman Coulter Life Sciences).
Image: The MoFlo XDP flow cytometer has set the standard for cell sorting with functionality, speed, and improved sensitivity (Photo courtesy of Beckman Coulter Life Sciences).
A major American producer of instruments for biomedical testing has acquired access to flow cytometry reagents that were among the first of this genre to be both dry and temperature-stable with CE marking for routine in vitro diagnostic use in Europe.

Beckman Coulter Life Sciences (Indianapolis, IN, USA), which develops, manufactures, and markets products that simplify, automate, and innovate complex biomedical testing has acquired the flow cytometry business assets of the life science technology company ReaMetrix India Pvt. Ltd. (Bangalore, India).

Beckman Coulter Life Sciences' diagnostic systems are found in hospitals and other critical care settings around the world and generate data used by physicians to diagnose disease, make treatment decisions, and monitor patients. In the research sector, their instruments have been applied to complex biological problems including causes of disease and potential new therapies or drugs. Acquisition of ReaMetrix is expected to help Beckman Coulter to widen its tool and technology offerings that would simplify the sample preparation process and provide highly standardized reagent combinations to cytometry laboratories around the globe. The deal provides it with temperature-stable, single-dose, multi-color antibody cocktails targeting two key segments for flow cytometry - HIV monitoring and clinical research.

“This acquisition provides both immediate opportunity and long-term value,” said Mario Koksch, vice president and general manager of the cytometry business unit at Beckman Coulter Life Sciences. “The simplification of customer workflows will be dramatic. We will be able to offer customers an extended line of market leading technology while expanding our reach within two key segments for flow cytometry—HIV monitoring and clinical research.”

“Over the last decade, ReaMetrix has been developing technologies that improve access of diagnostic testing through innovation,” said Bala S. Manian, CEO of ReaMetrix India Pvt. Ltd. “The development of room temperature stable unitized flow reagents used in diagnostics and life sciences is an important component of that effort. For ReaMetrix, Beckman Coulter Life Sciences represents an opportunity to provide the global customer with an integrated and optimized solution involving both hardware and reagents. From our point of view, we now have the best chance of benefiting the intended target population as well as impacting the productivity of cytometrists around the world. ”

Related Links:
Beckman Coulter Life Sciences
ReaMetrix India Pvt. Ltd.


comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: This novel, flexible film that can react to light is a promising step toward an artificial retina (Photo courtesy of the American Chemical Society).

Novel Nanofilm May Be Artificial Retina Precursor

Researchers have used advanced nanotechnology techniques to develop a light-sensitive film that has potential for future artificial retina applications. Investigators at the Hebrew University of Jerusalem... Read more

Drug Discovery

view channel
Image: Disruption and removal of malaria parasites by the experimental drug (+)-SJ733 (Photo courtesy of the University of California, San Francisco).

Experimental Antimalaria Drug Induces the Immune System to Destroy Infected Red Blood Cells

An experimental drug for the treatment of malaria was found to induce morphological changes in infected erythrocytes that enabled the immune system to recognize and eliminate them. Investigators at... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Business

view channel

R&D Partnership Initiated to Reduce Development Time for New Drugs

nanoPET Pharma, GmbH (Berlin, Germany) signed an open-ended framework contract with the international pharmaceutical company Boehringer Ingelheim (Ridgefield, CT, USA). By developing customized contrast agents for research in both basic and preclinical studies, nanoPET Pharma will contribute to the enhancement of Boehringer... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.